Allyx Therapeutics Announces License For The Treatment of Cognitive Deficits in Neurodegenerative Disorders From Bristol Myers Squibb And Yale
Allyx Therapeutics Announces License For The Treatment of Cognitive Deficits in Neurodegenerative Disorders From Bristol Myers Squibb And Yale Share Article Allyx Therapeutics expects to advance ALX-001, an mGluR5 modulator for Alzheimerโs disease, into clinical trials in 2021 NEW HAVEN, Conn. (PRWEB) January 13, 2021 Today, Allyx Therapeutics announced the completion of a license agreement with Bristol Myers Squibb to develop A...
United States Stephen Bloch John Puziss Yale University Yale School Of Medicine Professor Stephen Strittmatter Yale Office Of Cooperative Research
Source: prweb.com